Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06370130
Status:
COMPLETED
Last Update Posted:
2024-04-17
First Post:
2024-04-12
Brief Title:
Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion
Sponsor:
Aerospace Center Hospital
Organization:
Aerospace Center Hospital
Study Overview
Official Title:
Determation of Median Effective Dose of Propofol Combined With Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion in Female Patients
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective To prospectively determine the median effective dose ED50 of propofol for inhibiting a response to laryngeal mask airway LMA insertion when combined with different doses of esketamine in female patients
Methods Fifty-eight female patients aged 20-60 ASAⅠ-Ⅱ scheduled for elective hysteroscopy were enrolled and randomly divided into two groups one administered 02 mgkg of esketamine K1 group n 28 and the other 03 mgkg of esketamine K2 group n 30 The two groups received the corresponding doses of esketamine intravenously followed by an intravenous injection of propofol injection time was 30 s The initial dose of propofol was 2 mgkg and the dose ratio of propofol in the adjacent patients was 09 If there was a positive reaction to LMA insertion the dose ratio in the next patient was increased by one gradient and if not the dose ratio was decreased by one gradient The median effective dose ED50 95 effective dose ED95 and 95 confidence interval 95CI of propofol for inhibiting a response to LMA insertion in the two esketamine groups were calculated using a probit analysis
Methods Fifty-eight female patients aged 20-60 ASAⅠ-Ⅱ scheduled for elective hysteroscopy were enrolled and randomly divided into two groups one administered 02 mgkg of esketamine K1 group n 28 and the other 03 mgkg of esketamine K2 group n 30 The two groups received the corresponding doses of esketamine intravenously followed by an intravenous injection of propofol injection time was 30 s The initial dose of propofol was 2 mgkg and the dose ratio of propofol in the adjacent patients was 09 If there was a positive reaction to LMA insertion the dose ratio in the next patient was increased by one gradient and if not the dose ratio was decreased by one gradient The median effective dose ED50 95 effective dose ED95 and 95 confidence interval 95CI of propofol for inhibiting a response to LMA insertion in the two esketamine groups were calculated using a probit analysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None